CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 7 enrolled
Drug / intervention
Ferric carboxymaltosedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04269707
NCT04269707Phase 3Completed
CompareCT.gov

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron Under Study Protocol 1VIT17044

American Regent, Inc.·interventional·Posted Feb 17, 2020·Updated Mar 21, 2022

In Brief

A Phase 3 clinical trial evaluating Ferric carboxymaltose for Iron Deficiency Anemia. Completed, enrolled 7 participants across 2 sites.

Detailed Summary

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 17, 2020
Enrollment StartNov 19, 2019
Primary CompletionDec 30, 2020
Study CompletionJan 29, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.4 years ago

Interventions

Ferric carboxymaltosedrug

IV iron